Global Tinea Pedis Treatment Market 2017-2021

足白癬治療の世界市場2017-2021

◆タイトル:Global Tinea Pedis Treatment Market 2017-2021
◆商品コード:IRTNTR13481
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年6月14日
◆ページ数:71
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、足白癬治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、足白癬治療の世界市場規模及び予測などの情報をお届けいたします。

About Tinea Pedis Treatment Tinea pedis, also known as athlete’s foot, is caused by dermatophyte fungus on foot and can spread to toenails and hands. It is a dermatophyte infection of the soles of the feet and the interdigital spaces. Tinea pedis thrives in warm, humid conditions and is most common among young adult men. Tinea pedis can be transmitted through direct contact with an infected person or by touching surfaces contaminated with the fungus. This fungus lives in warm, moist environments and is found in showers, locker room floors, and swimming pools.

Technavio’s analysts forecast the global tinea pedis treatment market to grow at a CAGR of 3.03% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global tinea pedis treatment market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic drugs sales.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Tinea Pedis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GSK
• Exeltis USA
• Valeant
• Viamet Pharmaceuticals

[Other prominent vendors]
• Allergan
• Almirall
• Amgen
• Aqua Pharmaceuticals
• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Celgene
• Dermira
• Elorac
• F. Hoffmann-La Roche
• Galderma
• Genentech
• Hexima
• Hisamitsu Pharmaceutical
• Incyte
• Mayne Pharma
• MediQuest Therapeutics
• Meiji Seika Pharma
• Merz Pharmaceuticals
• Moberg Pharma
• Mylan Pharmaceuticals
• NanoBio
• NovaBiotics
• Novan
• Nuvo Research
• Polichem
• Promius Pharma
• Sanofi
• Seren Pharmaceuticals
• Sun Pharma
• Taro
• Teva Pharmaceutical
• Theravance Biopharma
• Tinea Pharmaceuticals

[Market driver]
• High unmet needs
• For a full, detailed list, view our report

[Market challenge]
• Increased availability of generics and alternative therapies
• For a full, detailed list, view our report

[Market trend]
• Increased funding for antifungal research
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Pipeline landscape

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by ROA
• Oral
• Topical

PART 08: Market segmentation by disease type
• Interdigital tinea pedis
• Vesicular tinea pedis

PART 09: Geographical segmentation
• Tinea pedis treatment market in Americas
• Tinea pedis treatment market in EMEA
• Tinea pedis treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Increased funding for antifungal research
• Increased focus on combination therapies
• Advent of novel therapies

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• GSK
• Valeant
• Exeltis USA
• Viamet Pharmaceuticals
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Symptoms of tinea pedis
Exhibit 02: Pipeline analysis
Exhibit 03: Global tinea pedis treatment market: Snapshot
Exhibit 04: Global tinea pedis treatment market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis: Global tinea pedis treatment market
Exhibit 06: Five forces analysis
Exhibit 07: Global tinea pedis treatment market by ROA 2016
Exhibit 08: Global tinea pedis treatment market by disease type 2016
Exhibit 09: Global interdigital tinea pedis treatment market 2016-2021 ($ millions)
Exhibit 10: Global vesicular tinea pedis treatment market 2016-2021 ($ millions)
Exhibit 11: Global tinea pedis treatment market by geography 2016 and 2021
Exhibit 12: Global tinea pedis treatment market by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Tinea pedis treatment market in Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Tinea pedis treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario of APAC
Exhibit 18: Tinea pedis treatment market in APAC 2016-2021 ($ millions)
Exhibit 19: Competitive structure analysis of global tinea pedis treatment market 2016
Exhibit 20: Strategic success factors of companies in global tinea pedis treatment market
Exhibit 21: GSK: Strength assessment
Exhibit 22: GSK: Strategy assessment
Exhibit 23: GSK: Opportunity assessment
Exhibit 24: Valeant: Key highlights
Exhibit 25: Valeant: Strength assessment
Exhibit 26: Valeant: Strategy assessment
Exhibit 27: Valeant: Opportunity assessment
Exhibit 28: Exeltis USA: Strength assessment
Exhibit 29: Exeltis USA: Strategy assessment
Exhibit 30: Exeltis USA: Opportunity assessment
Exhibit 31: Viamet Pharmaceuticals: Strength assessment
Exhibit 32: Viamet Pharmaceuticals: Strategy assessment
Exhibit 33: Viamet Pharmaceuticals: Opportunity assessment



【掲載企業】

GSK, Exeltis USA, Valeant, Viamet Pharmaceuticals, Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.

【資料のキーワード】

足白癬、足白癬治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[足白癬治療の世界市場2017-2021] (Global Tinea Pedis Treatment Market 2017-2021 / IRTNTR13481)販売に関する免責事項
[足白癬治療の世界市場2017-2021] (Global Tinea Pedis Treatment Market 2017-2021 / IRTNTR13481)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆